FTH1 and chronic kidney disease: Myeloid Fth1 deletion combined with iron therapy in CKD mice resulted in further improvement of kidney function as assessed by BUN (Supplemental Figure 10C) and further reduction of kidney fibrosis as evaluated by Masson’s trichrome staining (Supplemental Figure 10D) compared with iron therapy alone, indicating a synergistic antifibrotic effect of myeloid Fth1 deletion and iron therapy.